You are here

Morgane Rolland, Ph.D.

Chief, Viral Genetics Section

Biography

Dr. Morgane Rolland received her Ph.D. from the University of Bordeaux, France in 2003. She completed a post-doctoral fellowship with Professor James I. Mullins in the Microbiology department of the University of Washington in Seattle between 2004 and 2010.

Research

Dr. Rolland's interests focus on understanding features of HIV-1 genetics and evolution that are important to HIV vaccine-related research. The Rolland Lab studies the interplay between HIV-1 evolutionary dynamics and the host immune pressure in the context of HIV-1 natural infection or following vaccination. What are the characteristics of strains establishing infection? How do strains evolve within a host in response to immune pressure? How do strains adapt between hosts to spread globally?

Research topics include:


Acute/Early HIV-1 infection

Follow-up of high-risk volunteers in the RV217/ECHO cohort allows us to understand HIV-1 transmission, its adaptation to new hosts, and the development of immune escape.

Breakthrough HIV-1 infections in vaccine Trials

The analysis of HIV-1 breakthrough infections allows to understand the genetic consequences of vaccine-induced immune responses and can provide insights on potential mechanisms of vaccine protection.

HIV-1 vaccine design

Harnessing aspects of HIV-1 dynamics and evolution to develop better HIV-1 vaccine candidates.

Recent Publications

  •  Rolland M., Modjarrad K. Multiple co-circulating HIV-1 subtypes in the Middle East and North Africa. AIDS, Epub  18 June 2015.
     
  • Manocheewa S., Lanxon-Cookson E. C., Liu Y., Swain J. V., McClure J., Rao U., Maust B., Deng W., Sunshine JE., Kim M., Rolland M., Mullins JI. Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses.  J. Vis. Exp. (99), e52610, doi:10.3791/52610 (2015).
     
  • Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.
     
  • Ratto-Kim S., de Souza MS., Currier JR., Karasavvas N., Sidney J., Rolland M., Valencia-Micolta A., Madnote S., Sette A., Nitayaphan S., Pitisuttuthum P., Kaewkungwal J., Rerks-Ngarm S., O'Connell R., Michael N., Robb ML., Marovich M., Kim JH. Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS One. 2015 Feb 9;10(2):e0115582.